Alternate-Day Buprenorphine Administration. Phase II - 4
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00000222 |
|
Recruitment Status :
Completed
First Posted : September 21, 1999
Last Update Posted : June 24, 2005
|
Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborator:
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Primary Completion Date : | No date given |
| Study Completion Date : | No date given |
Publications:
Amass, bickel, Crean, Blake, Higgins (in press). Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology. Amass, Bickel, Crean, Blake, Higgins. (in press) Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology